Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

imulating the body's ability to produce insulin in response to elevated levels of blood sugar, inhibiting the release of a hormone called glucagon following meals, slowing the rate at which nutrients are absorbed into the bloodstream and reducing food intake.

About Diabetes

Diabetes affects more than 20 million in the United States and an estimated 246 million adults worldwide(4,5). Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States and costs approximately $132 billion per year in direct and indirect medical expenses(6).

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen(7).

Important Safety Information for BYETTA(R) (exenatide) injection

BYETTA improves glucose (blood sugar) control in patients with type 2 diabetes who are taking metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems with the stomach or food digestion, or those who have severe kidney disease. Before using BYETTA, patients should tell their healthcare provider if they are pregnant, plan to become pregnant, or are breastfeeding. BYETTA has not been studied in children.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is most common when first starting BYETTA, but decreases over time in most patients. BYETTA may reduce
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 2013 Velplex, LLC announced this week that ... that connects buyers and sellers of discount dental ... Why? It,s because the business leaders ... with the dental industry. They have 50 years of ... worked to negotiate some of the best prices in ...
(Date:6/17/2013)... , June 17, 2013 Vanda ... presented additional data today at ENDO 2013, the ... that tasimelteon can entrain (synchronize) both melatonin and ... to reset the master body clock and address ... Disorder (Non-24).  The SET (Safety and Efficacy of ...
(Date:6/17/2013)...  Hanger, Inc. (NYSE:  HGR) today announced the signing ... senior secured facilities to an aggregate of up to ... agreement includes a $200 million revolving credit facility and ... agreement was comprised of a $100 million revolving credit ... facility matures on June 17, 2018, and is subject ...
Breaking Medicine Technology:TopProdeals.com Rises to Top as Discount Dental Supply Leader 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3
... 2011 Watson Pharmaceuticals, Inc. (NYSE: ... has received U.S. Food and Drug Administration ("FDA") ... for Enoxaparin Sodium Injection in the 100mg/mL and ... equivalent to Sanofi-aventis, LOVENOX®, and is a low ...
... SYDNEY, Sept. 19, 2011 HeartWare International, Inc. (NASDAQ: ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled to present ... Device Day at 1:55 p.m. ET on Thursday, September ...
Cached Medicine Technology:Watson Pharmaceuticals Announces Approval of Amphastar's Generic LOVENOX(R) 2Watson Pharmaceuticals Announces Approval of Amphastar's Generic LOVENOX(R) 3HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day 2
(Date:6/17/2013)... 17, 2013 Daily Gossip Magazine has ... a thorough review of the Tinnitus Miracle treatment ... presents the natural treatment that Coleman suggests ... have tested it. , Based on the information provided ... Tinnitus treatment suggested by Thomas Coleman is different ...
(Date:6/17/2013)... New York, New York (PRWEB) June 17, 2013 ... associated with products manufactured by C.R. Bard, Inc. ... underway in New Jersey’s Atlantic County Superior Court, Bernstein ... a new Consent Order that set forth protocols for ... samples for the litigation’s bellwether cases. Court documents ...
(Date:6/17/2013)... June 17, 2013 The producers of ... new series of reports highlighting how sustainable farming techniques ... growing populations and their demand on food supplies. , ... produced television series airing in markets around the country ... legendary Martin Sheen, who is marking the start of ...
(Date:6/17/2013)... 2013 Ayurveda Chile is the ... or wisdom of life." As a mind-body-spirit medicine, its scope ... of consciousness. Its fundamental philosophy is that disease is the ... In order to re-establish optimal health, one must discover where ... life style which brings us back into perfect harmony and ...
(Date:6/17/2013)... York, NY (PRWEB) June 17, 2013 The ... Yohan Blake to attend the Festival this summer, which will ... 18th through Sunday, August 25th. , Blake professes the ... bananas a day to fuel his world class sprinting ... large volume of fruit is drawing attention. "Yohan Blake believes ...
Breaking Medicine News(10 mins):Health News:Thomas Coleman's Tinnitus Miracle Treatment Review Discloses Alternative Natural Cure 2Health News:Transvaginal Mesh Lawyers at Bernstein Liebhard LLP Note New Order in New Jersey C.R. Bard Litigation Concerning Handling of Explants and Tissue Samples 2Health News:Transvaginal Mesh Lawyers at Bernstein Liebhard LLP Note New Order in New Jersey C.R. Bard Litigation Concerning Handling of Explants and Tissue Samples 3Health News:Ayurveda Chile Program Offered by Escuela Ayurveda de California in August, 2013 2Health News:Yohan Blake Invited to The Woodstock Fruit Festival as Guest of Honor 2
... reports the latest research done in Britain claim that ... //cancer successfully after having studied over 2,400 patients. The ... effectiveness of adding the drug epirubicin to regular chemotherapy ... cancer. Both studies reported better results of treatment ...
... government officials continue to extol the virtues of the NHS, ... to protest against the policies of the NHS. // ... and increased staff numbers but NHS staff including doctors, nurses, ... of Westminster to protest aginst disastrous policies. ,Pensioners ...
... that has worked against different strains of Staphylococcus aureus ... promising step towards designing a vaccine which can be used ... study was done by researchers at the University of Chicago ... Infectious Diseases. , Dr. Olaf Schneewind and colleagues at ...
... at the Harvard Medical School and the National Institute on ... found in red wine, and the skin of red ... with calories and may significantly affect the longevity ... journal Nature, explains that a daily intake of ...
... medical consultations and patients are seen tapping the online ... ailments, especially ones they would like to hide in ... scored very high on the search list and back ... of attention.NHS direct, the helpline is known to answer ...
... less inclined to commit suicide as compared to Whites was ... among black Americans. Scientists from the University of Michigan said ... ones own life happens to be the 11th leading cause ... that nearly one in 10 black Americans suffer from suicidal ...
Cached Medicine News:Health News:Wide Differences between NHS staff and ministers 2Health News:Fat or old - Swig red wine to live long says study 2
... The model 55S Rocking Shaker provides ... and blotted membranes. The very slow ... degree of tilt provide a gentle ... over gels and blotted membranes to ...
Plate Roller...
Conversion Kits For Modular Incubator Chamber...
Multi-Tier Shaker...
Medicine Products: